GRHL2 and breast carcinoma: In our in-depth analysis utilizing chromatin accessibility, we determine the intratumor heterogeneity of breast cancer cells with a focus on ER signaling, and we identify distinct cell populations potentially driven by GRHL2 that may contribute to intrinsic resistance to endocrine therapy.